DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Cremolini C. et al.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Lancet Oncol 2015;
16: 1306-1315
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.